Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Acquisition of exclusive commercialization rights for European markets
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated
